Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocuronium neuromuscular blockade reversal effects on hypoxic and hypercapnic ventilatory responses in healthy volunteers
NL-OMON46872Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised trial of rocuronium, Sugammadex and neostigmine, sponsored by Leiden University Medical Center. Primary endpoints: Magnitude of the hypoxic ventilatory response and Magnitude of the hypercapnic ventilatory response. Started May 2017; status: active, not recruiting.
02
Drugs
rocuroniumSugammadexneostigmine
Beyond the preview
Go deeper on NL-OMON46872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46872.